Ftse Mib
34.531,58
-0,21%
DAX
18.673,07
-0,28%
S&P 500
5.321,41
0,25%
NASDAQ
16.832,62
0,22%
Bitcoin
70.010,10
-0,17%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Cadrenal Therapeutics Inc (CVKD) Cadrenal Therapeutics Inc (CVKD) Notizie

Cadrenal Therapeutics Inc

CVKD
0,42
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 13:00:00
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
09/5/202415:00PRNUSCadrenal Therapeutics Provides First Quarter 2024 Corporate..
09/5/202412:23EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/4/202422:30PRNUSCadrenal Therapeutics to Participate in Noble Capital..
09/4/202415:00PRNUSCadrenal Therapeutics Receives FDA Orphan Drug Designation..
11/3/202414:15EDGAR2Form 8-K - Current report
11/3/202414:00PRNUSCadrenal Therapeutics Provides Fourth Quarter 2023 Corporate..
05/3/202423:24EDGAR2Form 8-K - Current report
26/2/202415:00PRNUSCadrenal Therapeutics to Participate at Technology and Heart..
15/2/202414:00EDGAR2Form 8-K/A - Current report: [Amend]
12/2/202422:49EDGAR2Form 8-K - Current report
08/2/202415:00PRNUSCadrenal Therapeutics Appoints Jeff Cole as Chief Operating..
31/1/202415:00PRNUSCadrenal Therapeutics Highlights Publication of..
24/1/202415:00PRNUSCadrenal Therapeutics to Participate in a Fireside Chat at..
04/1/202415:00PRNUSCadrenal Therapeutics to Present at the Biotech Showcase on..
19/12/202315:00PRNUSNoble Capital Markets Initiates Coverage on Cadrenal..
12/12/202315:00PRNUSCadrenal Therapeutics Engages The Sage Group to Advance..
30/11/202322:15PRNUSCadrenal Therapeutics to Present at the NobleCon 19..
09/11/202315:15EDGAR2Form 8-K - Current report
09/11/202315:00PRNUSCadrenal Therapeutics Provides Third Quarter 2023 Corporate..
09/11/202314:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
23/10/202323:04EDGAR2Form 8-K - Current report
09/10/202322:15PRNUSCadrenal Therapeutics to Participate in the Lytham Partners..
08/9/202322:10EDGAR2Form 8-K - Current report
05/9/202314:00PRNUSCadrenal Therapeutics Highlights Additional Need for a New..
31/8/202322:05EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
31/8/202322:05EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
30/8/202314:00PRNUSCadrenal Therapeutics Expands Evaluation of Tecarfarin for..
28/8/202322:58EDGAR2Form ARS - Annual Report to Security Holders
28/8/202322:55EDGAR2Form DEF 14A - Other definitive proxy statements
28/8/202322:15PRNUSCadrenal Therapeutics to Participate in the H.C. Wainwright..
18/8/202312:06EDGAR2Form 8-K - Current report
16/8/202322:10EDGAR2Form 8-K - Current report
16/8/202322:05EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
10/8/202315:16EDGAR2Form 8-K - Current report
10/8/202315:00PRNUSCadrenal Therapeutics Provides Second Quarter 2023 Corporate..
10/8/202312:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/8/202315:00PRNUSCadrenal Therapeutics Expands Focus for Tecarfarin to..
01/8/202312:06EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
24/7/202315:20EDGAR2Form 8-K - Current report
24/7/202315:15EDGAR2Form S-1 - General form for registration of securities under..
24/7/202315:00PRNUSCadrenal Therapeutics Announces Appointment of Robert..
14/7/202322:52EDGAR2Form 8-K - Current report
14/7/202321:02PRNUSCadrenal Therapeutics Announces Closing of $7.5 Million..
12/7/202321:17PRNUSCadrenal Therapeutics Announces $7.5 Million Private..
01/6/202315:00PRNUSCadrenal Therapeutics to Participate in the 2023 BIO..
Apertura: Min: Max:
Chiusura: 0,42

La tua Cronologia

NASDAQ
CVKD
Cadrenal Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network